Potential Clinical Significance of a Plasma-Based <i>KRAS</i> Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer

Abstract

KRAS mutation in plasma DNA correlates with the mutation status in the matched tumor tissues of patients with NSCLC. Plasma KRAS mutation status is associated with a poor tumor response to EGFR-TKIs in NSCLC patients and may be used as a predictive marker in selecting patients for such treatment.